Dec 05, 2011
Montreal, Quebec – December 5, 2011– AmorChem Financial Inc. has announced two important developments in its activities as a venture capital fund focusing on life sciences projects in Quebec. They are the launch of a new medicinal chemistry contract research company, NuChem Therapeutics Inc., as well as the appointment of Dr. John Clement as its business development partner.
NuChem Therapeutics Inc. has started operations at Montreal’s Biotechnology Research Institute. Dr. Daniel Guay, formerly with Merck Canada and the Institut de Recherche en Immunologie et Cancérologie, has been chosen to lead the company, leading a team of seven scientists who also gained much of their experience at Merck Canada.
Read more »